Atorvastatin	B:C0286651
-	O
induced	O
dermatomyositis	O
.	O

Atorvastatin	O
-	O
induced	O
dermatomyositis	B:C0011633
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	B:C0026859
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	B:C0281822
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	B:C0027051
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	B:C0027051
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	B:C0332293
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	B:C0286651
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	B:C1620287
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	B:C0206460
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	B:C0012373
following	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
.	O

A	O
49	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	I:C0281822
who	O
had	O
a	O
myocardial	O
infarction	I:C0027051
(	O
myocardial	O
infarction	I:C0027051
)	O
was	O
treated	O
with	I:C0332293
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	B:C0337983
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	B:C0015230
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	B:C0332563
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	B:C0025525
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	B:C0015450
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	B:C0027530
,	O
as	O
well	O
as	O
proximal	O
muscle	I:C0221629
weakness	I:C0221629
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	I:C0337983
clinic	I:C0337983
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	B:C0221629
muscle	I:C0221629
weakness	I:C0221629
.	O

In	O
the	O
physical	B:C0031809
examination	I:C0031809
,	O
a	O
reddish	O
rash	I:C0015230
on	O
the	O
face	O
and	O
Gottron	O
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	O
were	O
detected	O
.	O

In	O
the	O
physical	O
examination	I:C0031809
,	O
a	O
reddish	B:C0015230
rash	I:C0015230
on	O
the	O
face	O
and	O
Gottron	O
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	O
were	O
detected	O
.	O

In	O
the	O
physical	O
examination	I:C0031809
,	O
a	O
reddish	O
rash	I:C0015230
on	O
the	O
face	B:C0015450
and	O
Gottron	O
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	O
were	O
detected	O
.	O

In	O
the	O
physical	O
examination	I:C0031809
,	O
a	O
reddish	O
rash	I:C0015230
on	O
the	O
face	O
and	O
Gottron	B:C0423781
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	O
were	O
detected	O
.	O

In	O
the	O
physical	O
examination	I:C0031809
,	O
a	O
reddish	O
rash	I:C0015230
on	O
the	O
face	O
and	O
Gottron	O
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	B:C0025525
were	O
detected	O
.	O

In	O
the	O
physical	O
examination	I:C0031809
,	O
a	O
reddish	O
rash	I:C0015230
on	O
the	O
face	O
and	O
Gottron	O
's	I:C0423781
papules	I:C0423781
on	O
the	O
knuckles	O
were	O
detected	B:C0442726
.	O

The	O
skin	B:C0150866
biopsy	I:C0150866
performed	O
indicated	O
interface	O
dermatitis	I:C0262981
with	O
hydropic	O
degeneration	I:C0333442
of	O
basal	O
keratinocytes	I:C0022567
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

The	O
skin	O
biopsy	I:C0150866
performed	O
indicated	O
interface	B:C0262981
dermatitis	I:C0262981
with	O
hydropic	O
degeneration	I:C0333442
of	O
basal	O
keratinocytes	I:C0022567
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

The	O
skin	O
biopsy	I:C0150866
performed	O
indicated	O
interface	O
dermatitis	I:C0262981
with	O
hydropic	B:C0333442
degeneration	I:C0333442
of	O
basal	O
keratinocytes	I:C0022567
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

The	O
skin	O
biopsy	I:C0150866
performed	O
indicated	O
interface	O
dermatitis	I:C0262981
with	O
hydropic	O
degeneration	I:C0333442
of	O
basal	B:C0022567
keratinocytes	I:C0022567
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

The	O
skin	O
biopsy	I:C0150866
performed	O
indicated	O
interface	O
dermatitis	I:C0262981
with	O
hydropic	O
degeneration	I:C0333442
of	O
basal	O
keratinocytes	I:C0022567
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	B:C0011633
.	O

He	O
was	O
started	O
on	O
prednisolone	B:C0032950
1	O
mg	O
/	O
kg	O
/	O
day	O
.	O

After	O
30	O
days	O
of	O
prednisolone	B:C0032950
therapy	O
,	O
all	O
symptoms	O
disappeared	O
.	O

After	O
30	O
days	O
of	O
prednisolone	O
therapy	O
,	O
all	O
symptoms	B:C1457887
disappeared	O
.	O

